EHA 2021 | GEM-CLARIDEX: improved CR rate but no difference in PFS at 19 months of follow-up
Noemí Puig, MD, PhD, University Hospital Salamanca, Salamanca, Spain, shares an update on the Phase III randomized GEM-CLARIDEX trial (NCT02575144) investigating lenalidomide and dexamethasone with and without clarithromycin in patients with newly diagnosed, previously untreated multiple myeloma. 286 patients patients with multiple myeloma were treated in the trial. At a median follow-up of 19 months, no significant differences in the median progression-free survival (PFS) were observed, despite a higher complete response (CR) rate in patients receiving additional clarithromycin. Dr Puig gives an overview of the key findings from the trial, in particular discussing the safety profile of clarithromycin plus lenalidomide and dexamethasone. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Noemi Puig, MD, PhD, has received honoraria from Amgen, Celgene, Janssen, Takeda and The Binding Site; has participated in a consulting or advisory role for Amgen, Celgene, Janssen and Takeda; has participated in speakers’ bureau for Celgene; and has received research funding from Celgene, Janssen, Amgen and Takeda.
